Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Grosbois

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
La Revue De Medecine Interne|October 16, 2002
[Follow-up of monoclonal gammopathy of undetermined significance in a population of 51 patients older than 70 years ]O Decaux, C Cazalets-Lacoste, B Cador-Rousseau, et al.
Pathologie-Biologie|December 1, 1987
[Value of computer processing of data acquired by cytofluorometry for biological analyses]G Merdrignac-Lenoan, J P le Pichon, P Pellen, et al.
La Revue De Medecine Interne|May 7, 2013
[100 essential drugs. An internal medicine approach]M Thomas, P Arlet, O Aumaitre, et al.
Pathologie-Biologie|August 31, 2015
Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patientsM-P Beaumont-Epinette, C Moreau, S Besnard, et al.
Journal of Clinical Immunology|January 1, 1993
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myelomaC Mathiot, J L Teillaud, M Elmalek, et al.
Leukemia Research|December 29, 1999
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphologyJ E Goasguen, M Zandecki, C Mathiot, et al.
European Journal of Haematology|January 1, 1996
Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM)O Mejjad, X Le Loët, J P Basuyau, et al.
The European Journal of Medicine|October 1, 1993
Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM)A Daragon, C Humez, C Michot, et al.
American Journal of Hematology|February 1, 1995
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)T Facon, J F Menard, J L Michaux, et al.
La Revue De Medecine Interne|January 1, 1993
[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums]C Mathiot, B Grosbois, J L Teillaud, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
La Revue De Medecine Interne|October 16, 2002
[Follow-up of monoclonal gammopathy of undetermined significance in a population of 51 patients older than 70 years ]O Decaux, C Cazalets-Lacoste, B Cador-Rousseau, et al.
Pathologie-Biologie|December 1, 1987
[Value of computer processing of data acquired by cytofluorometry for biological analyses]G Merdrignac-Lenoan, J P le Pichon, P Pellen, et al.
La Revue De Medecine Interne|May 7, 2013
[100 essential drugs. An internal medicine approach]M Thomas, P Arlet, O Aumaitre, et al.
Pathologie-Biologie|August 31, 2015
Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patientsM-P Beaumont-Epinette, C Moreau, S Besnard, et al.
Journal of Clinical Immunology|January 1, 1993
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myelomaC Mathiot, J L Teillaud, M Elmalek, et al.
Leukemia Research|December 29, 1999
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphologyJ E Goasguen, M Zandecki, C Mathiot, et al.
European Journal of Haematology|January 1, 1996
Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM)O Mejjad, X Le Loët, J P Basuyau, et al.
The European Journal of Medicine|October 1, 1993
Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM)A Daragon, C Humez, C Michot, et al.
American Journal of Hematology|February 1, 1995
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)T Facon, J F Menard, J L Michaux, et al.
La Revue De Medecine Interne|January 1, 1993
[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums]C Mathiot, B Grosbois, J L Teillaud, et al.
Pageof 8